Develop a coordinated strategy to attract the necessary funding to implement the clinical studies and research priorities as outlined in the position paper by Selby et al. (submitted to the PARENCHIMA special issue in NDT before May 2018).
Anna Caroli, Nicholas Selby, Steven Sourbron,Tim Leiner, Peter Blankestijn.
Peter Blankestijn, Clemens Bos, Anna Caroli, Christian Combe, Anneloes de Boer, Sophie De Seigneux, Kai- Uwe Eckardt, Nuria Garcia Fernandez, Anita Harteveld, Paul Hockings, Nicolas Grenier, Matthias Günther (ESMRMB), Jaap Joles, Philip Kalra, Tim Leiner, Per Liss, Patrick Mark, Iosif Mendichovszky, Michael Nation (KRUK), Aghogho Odudu, Aaron Oliver-Taylor, Alberto Ortiz, Doug Pendsè, Norberto Perico, Menno Pruijm, Arjen Rienks (DKF), Nicholas Selby, Roslyn Simms, Janka Slatinska,Steven Sourbron, Maarten Taal,Harriet Thoeny, Jean-Paul Vallee, Marcos Wolf.
The Netherlands, UK, Italy, Spain, France, Sweden, Switzerland, Austria, Czech Republic and Germany.
The minutes of the meeting can be found here.
[8.15 - 8.30] Coffee and Welcome
[8.30 - 9.00] Introductions
[9.00 - 09.20] PARENCHIMA WG3 - where we are now and what we aim to do.
[9.20 - 10.30] Session 1: Ongoing renal initiatives – any room for renal MRI? (chair: Phil Kalra)
[10.30 - 11.00] Coffee break
[11.00 - 12.30] Session 2: Potential support for collaborative renal MRI research (chair: Tim Leiner)
[12.30 - 13.00] Session 3: Renal MRI biomarkers: the way to go (chair: Marcos Wolf)
[13.00 - 14.00] Light lunch
[14.00 - 14.30] WG3 roadmap definition - clinical areas, study scale and design, funding strategy (chair: Patrick Mark)
[14.30 - 16.00] Small group sessions (specific clinical and practical planning for grants)
[16.00 - 16.30] Plenary session (group session report, definition of actions)